Last updated 2026-07-20
- Raised $1.7M Pre-Seed round led by VLX Ventures, Apr 2025
Total raised
$1.7M
Last: Undisclosed Round 2025-05
Stage
Pre-Seed
Founded
2022
Headcount
8
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences
About
Sakura Bio is an innovative biotech company transforming the future of cell therapy with effective, durable, and accessible T and NK cell treatments. Their core technology, T-Boost, enhances the potency, persistence, and resistance of reprogrammed T and NK cells against the tumor microenvironment. They are developing an off-the-shelf, allogeneic T-cell therapy, with their lead product, SAK-T (Super Activated Killer T-cell), being a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity to healthy tissue.
Funding history · 1 round · $1.7M total
2025-04
Pre-Seed
$1.7M
★ VLX Ventures
Headcount over time
From 5 (2023-03) to 7 (2025-12) · +2 (+40%) · 7 points · source: Finder history + radar grounding
Q&A
- What is Sakura Bio's primary focus?
- Sakura Bio focuses on developing an off-the-shelf, naïve PBMC-derived allogeneic T-cell therapy to combat cancer, specifically acute myeloid leukemia.
- What is Sakura Bio's lead product?
- Sakura Bio's lead product is Super Activated Killer T-cell (SAK-T), a unique T-cell population designed for superior anti-tumor cytotoxic activity without toxicity to healthy tissue.
- What is the safety profile of SAK-T cells compared to other T-cell products?
- SAK-T cells have a high safety profile, with no graft-versus-host disease, distinguishing them from other T-cell-based products like CAR-T.
- What is the first-in-human indication for SAK therapy?
- Due to SAK-T's killing properties of leukemic cells, Sakura Bio has chosen acute myeloid leukemia as its first-in-human indication for SAK therapy.
- When was Sakura Bio founded?
- Sakura Bio was founded in October 2022.
- How many employees does Sakura Bio currently have?
- Sakura Bio has 1-10 employees.
- What is Sakura Bio's current funding stage?
- Sakura Bio is currently in the Pre-Seed funding stage.
- What is the total amount of funding raised by Sakura Bio?
- Sakura Bio has raised a total of $1,700,000.
- When did Sakura Bio complete its last funding round and who were the lead investors?
- In May 2025, Sakura Bio completed a funding round with.
Team · 2
Dikla Berko-Ashur
Founder · Co-founder & CEO
Amnon Peled
Founder · Co-founder & CTO
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcareLaboratories
Business model
B2B2CB2B
Tags
cancercell-therapycancer-therapypharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | sakurabio.com/ |
|---|---|
| linkedin.com/company/86832778 |
Identifiers & details
| Founded | 2022-10 |
|---|---|
| Employees (exact) | 8 |
Radar intelligence
Web history (Wayback)
| Domain | sakurabio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516610532 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2022-05-11 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 4 — people (3), shares_capital (1) |
| Registered address | הברזל 32 תל אביב - יפו |
Recent registry events
| Date | Event |
|---|---|
| 2026-02-09 | עדכון דירקטורים-הסרת דירקטור |
| 2026-02-09 | העברת מניות |
| 2026-01-01 | עדכון דירקטורים-הוספת דירקטור |
| 2026-01-01 | עדכון בעלי תפקידים |